← All trials
NCT01501136
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2011
- Primary completion
- Dec 31, 2015
- Completion date
- May 31, 2019
- First posted
- Dec 29, 2011
- Last posted
- Jul 17, 2015
- Enrollment
- 200
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhengzhou UniversityLead sponsor
- Guizhou Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Henan Medical UniversityCollaborator
- Zhengzhou UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Wuhan UniversityCollaborator
- Xinyang Central HospitalCollaborator
- Zhengzhou UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.